Should all patients with chronic kidney disease receive an EPO-type drug?
Jeffrey S
JS
Berns
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa